Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 500 | 42% |
| 2020 | 3 | 415 | 45% |
| 2021 | 1 | 423 | 48% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nevada; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 16 | 4,592−1.4%/yr | −1.4%/yr | 1.4 | 0% | 5,470 in 2030+3%/yr |
| Arizona | 9 | 1,209 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 24 | 1,609−1.2%/yr | −1.2%/yr | 6.01.0× | 0% | 1,850 in 2030+2.4%/yr |
| Cholecystectomy & appendectomy |
Colorectal resection in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
| 2024 |
| 409 |
| 56% |
| 2025 est. | ≈ 410 | – |
| 2026 est. | ≈ 420 | – |
| 2022 | 1 | 405 | 51% |
| 2023 | 4 | 414 | 54% |
| 2024 | 3 | 409 | 56% |
| 2025 from claims | – | 412 333–484 | 57% |
| 2026 forecast | – | 419 328–526 | 57% |
| 2027 forecast | – | 424 314–560 | 58% |
| 2028 forecast | – | 428 303–591 | 58% |
| 2029 forecast | – | 433 294–621 | 59% |
| 2030 forecast | – | 437 287–649 | 60% |
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −3.2%/yr |
| 1.7 |
| 0% |
| 1,270 in 2030+0.9%/yr |
| Washington | 4 | 1,073−5.1%/yr | −5.1%/yr | 1.4 | 0% | 1,020 in 2030−0.9%/yr |
| Colorado | 2 | 764−2.7%/yr | −2.7%/yr | 1.6 | 0% | 860 in 2030+2.1%/yr |
| Oregon | 1 | 627−4.1%/yr | −4.1%/yr | 1.5 | 0% | 710 in 2030+2%/yr |
| Utah | 1 | 352−0.3%/yr | −0.3%/yr | 1.6 | 0% | 360 in 2030+0.4%/yr |
| Montana | 2 | 340−0.4%/yr | −0.4%/yr | 1.8 | 0% | 360 in 2030+1%/yr |
| Idaho | 0 | 307−1.1%/yr | −1.1%/yr | 1.5 | 0% | 320 in 2030+0.6%/yr |
| New Mexico | 0 | 182−11%/yr | −11%/yr | 0.8 | 0% | 170 in 2030−1.5%/yr |
| Alaska | 0 | 161−1.8%/yr | −1.8%/yr | 1.3 | 0% | 170 in 2030+1.2%/yr |
| Wyoming | 0 | 105−1.1%/yr | −1.1%/yr | 1.0 | 0% | 110 in 2030+0.6%/yr |
| 21 |
| 1,144−2.4%/yr |
| −2.4%/yr |
| 4.11.1× |
| 0% |
| 1,330 in 2030+2.6%/yr |
| Antireflux & hiatal hernia surgery | 2 | 177−7.6%/yr | −7.6%/yr | 0.60.9× | 0% | 200 in 2030+2.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 89% of company spending on these surgeons in 2025, −4 pts on 2024.
In 2025, 3 companies reported engagement with Nevada’s surgeons worth $51K in consulting, speaking, meals and travel tied to these products, about $17K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.